~22 Presentations at ASGCT, Including New Preclinical Data on Gene Therapy Candidates, Highlight uniQures Industry-Leading Research and Technology Capabilities ~

LEXINGTON, Mass. and AMSTERDAM, April 28, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 22 data presentations, of which five are oral presentations, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Virtual 2020 Annual Meeting being held May 12-15.

"uniQures significant scientific presence at this years ASGCT Annual Meeting demonstrates the robustness of our research capabilities and our excellence in developing novel technologies and commercial-scale gene therapy manufacturing, stated Sander van Deventer, executive vice president of research and product development at uniQure. We are very pleased to present new preclinical data on our gene therapy candidates for hemophilia A, spinocerebellar ataxia type 3, Fabry disease and data on our advances in technology and manufacturing.

Specific details on uniQures virtual oral presentations at ASGCT include:

Title: One-Time Intrathecal Administration of AAV5-miATXN3 in Non-Human PrimatesDate and Time: Wednesday May 13, 4:15 p.m. EDT/ 10:15 p.m. CET

Title: A Novel NAGA Variant Designed to be Non-immunogenic In Humans and Provide Broad Cross-Correction in Fabry DiseaseDate and Time: Thursday May 14, 4:15 p.m. EDT/ 10:15 p.m. CET

Title: A Single Administration of AAV5-hFIX in Newborn, Juvenile and Adult Mice Leads to Stable hFIX Expression up to 18 Months after DosingDate and Time: Thursday May 14, 4:15 p.m. EDT/ 10:15 p.m. CET

Title: Characterizing Next-Generation Baculovirus Transduction Processes - A Quality by Design-based Approach for AAV ManufacturingDate and Time: Friday May 15, 10:45 a.m. EDT/ 4:45 p.m. CET

Title: Clearance of Vector DNA From Bodily Fluids in Patients with Severe or Moderate-Severe Hemophilia B Following Systemic Administration of AAV5-hFIX and AAV5-hFIX PaduaDate and Time: Friday May 15, 11:15 a.m. EDT/ 5:15 p.m. CET

The following presentations were approved for poster presentation:

The abstracts were published today at the ASGCT Annual Meeting website.

About uniQure

uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.www.uniQure.com

Originally posted here:
uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting - Yahoo Finance

Comments are closed.